Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The debt to equity ratio is 0.00 as of the fiscal period ended Wednesday, December 31, 2025.
Reported quarterly debt to equity ratio; no daily interpolation. Q4 FY2025 (2025-12-31): 0.00.
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.00
DEBT TO EQUITY RATIO AVG 3Y
0.00
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
-100.00%
vs the sector median at left
Anbio Biotechnology Class A Ordinary Shares
Market Cap
$214.63M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
N/A
Market Cap
$215.21M
Debt to Equity Ratio
0.13
TTM Avg
0.20
3Y Avg
0.12
5Y Avg
0.08
Market Cap
$222.70M
Debt to Equity Ratio
0.06
TTM Avg
0.04
3Y Avg
0.04
5Y Avg
0.03
Market Cap
$214.64M
Debt to Equity Ratio
0.03
TTM Avg
0.05
3Y Avg
0.09
5Y Avg
0.10
Market Cap
$222.69M
Debt to Equity Ratio
0.15
TTM Avg
0.08
3Y Avg
0.14
5Y Avg
0.10
Market Cap
$214.10M
Debt to Equity Ratio
0.16
TTM Avg
0.18
3Y Avg
0.13
5Y Avg
0.12
Market Cap
$210.78M
Debt to Equity Ratio
0.21
TTM Avg
0.16
3Y Avg
0.18
5Y Avg
0.12
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anbio Biotechnology Class A Ordinary Shares (NNNN) | $214.63M | 0.00 | 0.00 | 0.00 | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $215.21M | 0.13 | 0.20 | 0.12 | 0.08 |
| Keros Therapeutics, Inc. (KROS)vs › | $222.70M | 0.06 | 0.04 | 0.04 | 0.03 |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 0.03 | 0.05 | 0.09 | 0.10 |
| Profound Medical Corp. (PROF)vs › | $222.69M | 0.15 | 0.08 | 0.14 | 0.10 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.10M | 0.16 | 0.18 | 0.13 | 0.12 |
| Compugen Ltd. (CGEN)vs › | $211.33M | 0.03 | 0.04 | 0.03 | 0.03 |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.78M | 0.21 | 0.16 | 0.18 | 0.12 |
| Vogenx Inc. (VOGX)vs › | $226.38M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $207.93M | 0.38 | 0.42 | 0.43 | 0.50 |
Debt/Equity
0.00
Current Ratio
344.31
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-12-31 | 0.00 |
| 2025-09-30 | 0.00 |
| 2025-06-30 | 0.00 |
| 2024-12-31 | 0.00 |
| 2024-06-30 | 0.00 |
| 2023-12-31 | 0.00 |
| 2023-06-30 | 0.00 |
| 2022-12-31 | 0.00 |
